Spyre Therapeutics CMO's Stock Sale Occurs Amid Strong Clinical and Financial Progress
The Chief Medical Officer of Spyre Therapeutics Inc., Sheldon Sloan, sold a notable amount of common stock on June 3, 2026. This transaction occurred despite the company's shares trading near their 52-week high following substantial recent returns. The sale was structured through pre-arranged trading plans and follows multiple significant corporate…